Outcomes in patients with spinal muscular atrophy and four or more SMN2 copies treated with onasemnogene abeparvovec: Findings from RESTORE

被引：0
|
作者：
Finkel, R. [1 ]
Benguerba, K. [2 ]
Reid, A. [3 ]
Raju, D. [4 ]
Faulkner, E. [4 ]
LaMarca, N. [4 ]
Servais, L. [5 ]
机构：
[1] St Jude Childrens Res Hosp, 332 N Lauderdale St, Memphis, TN 38105 USA
[2] Novartis Gene Therapies Switzerland GmbH, Rotkreuz, Switzerland
[3] Novartis Global RWE Gene Therapies, London, England
[4] Novartis Gene Therapies Inc, Bannockburn, IL USA
[5] Univ Oxford, Oxford, England
来源：
NEUROMUSCULAR DISORDERS | 2022年 / 32卷
关键词：
D O I：
10.1016/j.nmd.2022.07.073
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.37
引用
收藏
页码：S59 / S59
页数：1
相关论文
共 50 条
  • [31] Correlation between SMN2 copy number and clinical phenotype of spinal muscular atrophy:: three SMN2 copies fail to rescue some patients from the disease severity
    Harada, Y
    Sutomo, R
    Sadewa, AH
    Akutsu, T
    Takeshima, Y
    Wada, H
    Matsuo, M
    Nishio, H
    JOURNAL OF NEUROLOGY, 2002, 249 (09) : 1211 - 1219
  • [32] Effect on maximal mouth opening in children with spinal muscular atrophy treated with onasemnogene abeparvovec
    Beri, Nidhi
    Kapoor, Lekha
    Parashar, Deepak
    Mundada, Vivek
    ARCHIVES OF DISEASE IN CHILDHOOD, 2023, 108 (10) : 866 - 867
  • [33] Safety and Efficacy of IV Onasemnogene Abeparvovec for Pediatric Patients With Spinal Muscular Atrophy
    Mcmillan, Hugh J.
    Baranello, Giovanni
    Farrar, Michelle A.
    Zaidman, Craig M.
    Moreno, Teresa
    De Waele, Liesbeth
    Jong, Yuh-Jyh
    Laugel, Vincent
    Quijano-Roy, Susana
    Mercuri, Eugenio
    Chien, Yin-Hsiu
    Straub, Volker
    Darras, Basil T.
    Seibert, Julia
    Bernardo Escudero, Roberto
    Alecu, Iulian
    Freischlaeger, Frank
    Muntoni, Francesco
    NEUROLOGY, 2025, 104 (02)
  • [34] Spinal Muscular Atrophy Patients Treated with Onasemnogene Abeparvovec through a Managed Access Program: A Case Series
    Schultz, M.
    Richardson, R.
    Patterson, K.
    ANNALS OF NEUROLOGY, 2019, 86 : S132 - S133
  • [35] A Positive Modifier of Spinal Muscular Atrophy in the SMN2 Gene
    Prior, Thomas W.
    Krainer, Adrian R.
    Hua, Yimin
    Swoboda, Kathryn J.
    Snyder, Pamela C.
    Bridgeman, Scott J.
    Burghes, Arthur H. M.
    Kissel, John T.
    AMERICAN JOURNAL OF HUMAN GENETICS, 2009, 85 (03) : 408 - 413
  • [36] SMN2 and NAIP gene dosages in Vietnamese patients with spinal muscular atrophy
    Tran, Van Khanh
    Sasongko, Teguh Haryo
    Hong, Dang Diem
    Hoan, Nguyen Thi
    Dung, Vu Chi
    Lee, Myeong Jin
    Gunadi
    Takeshima, Yasuhiro
    Matsuo, Masafumi
    Nishio, Hisahide
    PEDIATRICS INTERNATIONAL, 2008, 50 (03) : 346 - 351
  • [37] Outcomes of Single-Agent Onasemnogene Abeparvovec or Nusinersen, and of Nusinersen Switching to Onasemnogene Abeparvovec, in Patients With Spinal Muscular Atrophy: Results of a Provider Survey in the United States
    Yang, Min
    Georgieva, Mihaela
    Wu, Eric
    Dabbous, Omar
    LaMarca, Nicole
    Shenouda, Lydia
    Patel, Anish
    Jimenez, Walter Toro
    Bischof, Matthias
    Minkoff, Neil
    NEUROLOGY, 2021, 96 (15)
  • [38] Treatments and Outcomes for Patients with Spinal Muscular Atrophy Type 2: Findings from RESTORE Registry
    Servais, Laurent
    Benguerba, Kamal
    De Vivo, Darryl C.
    Kirschner, Jan
    Muntoni, Francesco
    Proud, Crystal
    Tizzano, Eduardo
    Quijano-Roy, Susana
    Desguerre, Isabelle
    Saito, Kyoko
    Raju, Dheeraj
    LaMarca, Nicole
    Sun, Rui
    Anderson, Fred
    Faulkner, Eric
    Finkel, Richard
    NEUROLOGY, 2023, 100 (17)
  • [39] SOCIETAL COSTS OF SPINAL MUSCULAR ATROPHY TYPE 1 FOR PATIENTS TREATED WITH ONASEMNOGENE ABEPARVOVEC OR NUSINERSEN IN THE UNITED KINGDOM
    Kleintjens, J.
    Patel, A.
    van Keep, M.
    Srivastava, K.
    McHale, P.
    Affinito, S.
    Bischof, M.
    VALUE IN HEALTH, 2024, 27 (06) : S135 - S135
  • [40] Safety and efficacy of intravenous onasemnogene abeparvovec in patients with spinal muscular atrophy: interim findings from the phase 3 SMART study
    McMillan, H.
    Baranello, G.
    Farrar, M.
    Zaidman, C.
    Seibert, J.
    Bernardo, R.
    Alecu, I.
    Freischlager, F.
    Muntoni, F.
    NEUROMUSCULAR DISORDERS, 2023, 33 : S191 - S191
12345